3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
News 2026-10-07 11:32 UTC
(MORE TO FOLLOW) Dow Jones Newswires October 07, 2026 07:32 ET (11:32 GMT) Copyright (c) 2026 Dow Jones & Company, Inc. The statements in this document shall not be considered as an objective or independent explanation of the matters. Please note that this document (a) has not been prepared in accordance with legal req
News 2026-10-07 11:30 UTC
The FDA STAR pilot program aims to shorten the time from a complete supplemental new drug application submission to the action date. Entry into the STAR program qualifies plozasiran for a 6-month Priority Review, compared to a 10-month standard review.
News 2026-10-07 11:30 UTC
FDA STAR pilot program aims to shorten the time from complete supplement submission to the action date to allow earlier patient access to therapies that address an unmet medical need PASADENA, Calif.--()--October 07, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and D